OCCIDENT is a venture capital investor that operates internationally. The firm is interested in early-stage venture as well as seed opportunities. The firm was founded in 1993 in Zug, Zug, Switzerland.
The firm is interested in managing wealth in sustainable companies that contribute positively towards society. OCCIDENT is interested in long-term oriented, innovative start-ups and visionary founders. The firm is fascinated by technology sound topics such as deep tech, life sciences, digital and high tech sectors.
Tubulis Therapeutics is a Munich-based therapeutics company developing matched protein-drug conjugates.
GNA Biosolutions is a Martinsried-based molecular diagnostics company.
AdvanceCOR is a Planegg-based company developing drugs and diagnostics for the treatment of cardiovascular diseases founded in 2012 by Martin Lohse.